<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846650</url>
  </required_header>
  <id_info>
    <org_study_id>KPTB-1.1</org_study_id>
    <nct_id>NCT01846650</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Capecitabine Tablets</brief_title>
  <official_title>A Bioequivalence Study of Capecitabine Tablets in Patients of Locally Advanced or Metastatic Breast Cancer or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg
           (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets
           (Manufactured by Roche Pharma AG)

        2. Experimental Design： Two-period crossover design

        3. Test drug: Capecitabine tablets Reference drug: XELODA

        4. Sample size：24
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 0.33,0.67，1,1.5,2，2.5，3,4，5,6，8,hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Metastatic Breast Cancer or Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral Capecitabine tablets 2000mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELODA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral XELODA 2000mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine tablets</intervention_name>
    <description>Single oral Capecitabine tablets 2000mg qd</description>
    <arm_group_label>Capecitabine tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELODA</intervention_name>
    <description>Single oral XELODA 2000mg qd</description>
    <arm_group_label>XELODA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histopathologically /cytologically confirmed breast cancer or
             colorectal cancer，without chemotherapy or only adjuvant chemotherapy, and had
             previously received one or two standard chemotherapy regimens for patients;

          -  Age: 18-70 years, gender: both，BMI≥17，Eastern Cooperative Oncology Group (ECOG)
             performance status：0-2，Life expectancy greater than 3 months;

          -  Patients must have normal bone marrow function, liver and kidney function; adequate
             organ function in the last 1 week, meeting the following: ANC≥1.5×109/L，PLT≥80×109/L,
             Total bilirubin≤1.5×the upper limit of normal, ALT,AST≤2.5×the upper limit of normal,
             creatinine≤1.5×the institutional upper limit of normal.

          -  Patients who has retreatment could be enrolled at least 4 weeks after the last
             chemotherapy and radiotherapy.

          -  Patients must volunteer to participate and sign informed consent form.

        Exclusion Criteria:

          -  Suffering from heart, liver, kidney disease or severe acute and Organ invasion
             disease;

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity
             to 5-fluorouracil, or known DPD (Dihydropyrimidine Dehydrogenase) deficiency.

          -  Pregnant or breast-feeding female

          -  Only bone metastasis lesions, no other measurable lesions

          -  Known brain metastasis or history of organ transplantation

          -  Have long-term systemic steroid therapy

          -  Serious diseases of vital organs; other malignancies which is not cure

          -  Use of chemotherapy in the last 4 weeks

          -  History of drug/alcohol addiction or a positive hepatitis screen including hepatitis B
             surface antigen, HCV or HAV (IgM) antibodies

          -  Patient having abnormal serum calcium level at screening visit which as judged by
             Investigator could lead to safety risk to the patient upon participation in the trial
             or could interfere with the conduct of the trial.

          -  Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI CTCAE
             criteria or known, existing uncontrolled coagulopathy.

          -  Subjects are thought unsuitable for the study by investigators;

          -  Inability to comply with protocol or study procedures in the opinion of the
             investigator;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Ai dong, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Fourth Military Medical University</name>
      <address>
        <city>Xi an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>September 28, 2013</last_update_submitted>
  <last_update_submitted_qc>September 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

